- Home
- WFF vs CNTX Comparison
WFF vs CNTX Comparison
Compare WFF & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WFF | CNTX |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 102.9M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WFF | CNTX |
|---|---|---|
| Price | $0.50 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 42.6K | ★ 485.5K |
| Earning Date | 04-30-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $4,572,290.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $107.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.49 |
| 52 Week High | $29.26 | $1.61 |
Technical Indicators
Market Signals| Indicator | WFF | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.47 | 43.47 |
| Support Level | $0.50 | $0.99 |
| Resistance Level | $0.59 | $1.10 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 6.25 | 24.37 |
Price Performance
Historical ComparisonAbout WFF WF Holding Limited Ordinary Shares
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.